Institutional investors purchased a net $27.7 thousand shares of MYGN during the quarter ended June 2017 and now own 124.87% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
THRIVENT INVESTMENT MANAGEMENT, ... Bought 2.7 Million shares of Myriad Genetics Inc
DIMENSIONAL FUND ADVISORS LP Bought 787.4 Thousand shares of Myriad Genetics Inc
NORTHERN TRUST INVESTMENTS, INC. Bought 306.3 Thousand shares of Myriad Genetics Inc